Manufacturer of Controlled Substances; Notice of Application; Morton Grove Pharmaceuticals, 69133 [2013-27490]
Download as PDF
<![CDATA[
69133
Federal Register / Vol. 78, No. 222 / Monday, November 18, 2013 / Notices
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 17, 2014.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–27488 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey, Inc.
Manufacturer of Controlled
Substances; Notice of Registration;
Lin Zhi International, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 5, 2013,
Johnson Matthey, Inc., Pharmaceuticals
Materials, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
By Notice dated May 14, 2013, and
published in the Federal Register on
May 22, 2013, 78 FR 30332, Lin Zhi
International, Inc., 670 Almanor
Avenue, Sunnyvale, California 94085,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Morton Grove Pharmaceuticals
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on October 7, 2013,
Morton Grove Pharmaceuticals, 6451
Main Street, Morton Grove, Illinois
60053–2633, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Gamma
Hydroxybutyric Acid (2010), a basic
class of controlled substance listed in
schedule I.
The company plans to manufacture a
controlled substance for product
development.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 17, 2014.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–27490 Filed 11–15–13; 8:45 am]
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution and sale to its
customers.
The Thebaine (9333) will be used to
manufacture other controlled substances
for sale in bulk to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 17, 2014.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–27483 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
I
Drug
Tetrahydrocannabinols (7370) .....
3,4-Methylenedioxymethamphetamine (MDMA) (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
20:39 Nov 15, 2013
Jkt 232001
PO 00000
Frm 00094
Fmt 4703
I
I
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances as bulk
reagents for use in drug abuse testing.
In reference to drug code 7370 the
company plans to bulk manufacture a
synthetic Tetrahydrocannabinol. No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: November 4, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–27486 Filed 11–15–13; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
Schedule
Sfmt 9990
E:\FR\FM\18NON1.SGM
18NON1
]]>Agencies
[Federal Register Volume 78, Number 222 (Monday, November 18, 2013)]
[Notices]
[Page 69133]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-27490]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Morton Grove Pharmaceuticals
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 7, 2013, Morton Grove
Pharmaceuticals, 6451 Main Street, Morton Grove, Illinois 60053-2633,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric
Acid (2010), a basic class of controlled substance listed in schedule
I.
The company plans to manufacture a controlled substance for product
development.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 17, 2014.
Dated: November 5, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-27490 Filed 11-15-13; 8:45 am]
BILLING CODE 4410-09-P
